Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

Completed · Not applicable

Conditions studied: Pulmonary Arterial Hypertension

In brief

The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.

Key facts

Study ID

NCT00566423

Run by

Northwell Health

People needed

75

Starts

2007-05-01

Expected to finish

2010-06-01

Last updated by the study team

2011-06-23

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of PAH, based on currently accepted gold standard for Right Heart Catheterization.
• Patients with mean artery pressure of greater that 25 mm Hg at rest or 30mm Hg during exercise with pulmonary capillary wedge pressure less than 18mm Hg on right heart catheterization.

You may not qualify if…

• Significant left heart disease or renal insufficiency (serum creatinine > 1.5 mg%).

Where it is running

• North Shore-Long Island Health System — New Hyde Park, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.